Trials / Active Not Recruiting
Active Not RecruitingNCT05880706
A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 198 (actual)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 for injection and BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with locally advanced or metastatic non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BL-B01D1 | Administration by intravenous infusion |
| DRUG | Osimertinib Mesylate Tablets | Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily. |
Timeline
- Start date
- 2023-07-19
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2023-05-30
- Last updated
- 2025-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05880706. Inclusion in this directory is not an endorsement.